28/08/2026 NMPA Approves ATLED (Fanregratinib) for FGFR2+ Intrahepatic Cholangiocarcinoma NMPA Approves ATLED (Fanregratinib) for FGFR2+ Intrahepatic Cholangiocarcinoma (Ref) China’s NMPA has conditionally approved HUTCHMED's ATLED (fanregratinib, HMPL‑453), a selective FGFR1/2/3 inhibitor, for adult patients with advanced, metastatic, or unresectable intrahepatic cholangiocarcinoma (ICC) harboring FGFR2 fusions/rearrangements after prior systemic therapy The approval is supp

28/01/2026 Elevar Therapeutics submitted a NDA to the US FDA for lirafugratinib as a 2L treatment for cholangiocarcinoma Elevar Therapeutics submitted a NDA to the US FDA for lirafugratinib as a 2L treatment for cholangiocarcinoma (Ref) Elevar Therapeutics submitted a NDA to the US FDA for lirafugratinib (FGFR2 inhibitor) as a second-line treatment option for cholangiocarcinoma (CCA) patients with FGFR2 fusion or rearrangement. Dong-Gun Kim, the company’s chief executive offi